Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onapristone in Combination With Fulvestrant for ER-positive, HER2-negative Metastatic Breast Cancer
NCT04738292Phase 2Terminated
- Sponsor
- University of Wisconsin–Madison
- Start
- Oct 2021
- Primary completion
- Apr 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of onapristone extended release in breast cancer, sponsored by University of Wisconsin–Madison. Started Oct 2021; status: terminated.
02
Drugs
onapristone extended release
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04738292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04738292.